home / stock / alzn / alzn quote
Last: | $3.81 |
---|---|
Change Percent: | -2.83% |
Open: | $4 |
Close: | $3.81 |
High: | $4.16 |
Low: | $3.62 |
Volume: | 26,595 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.81 | $4 | $3.81 | $4.16 | $3.62 | 26,595 | 07-26-2024 |
$3.89 | $3.75 | $3.89 | $4.24 | $3.75 | 67,365 | 07-25-2024 |
$3.64 | $3.82 | $3.64 | $3.891 | $3.6201 | 10,650 | 07-24-2024 |
$3.7549 | $3.63 | $3.7549 | $4.1 | $3.45 | 27,574 | 07-23-2024 |
$3.52 | $3.72 | $3.52 | $3.72 | $3.27 | 13,029 | 07-22-2024 |
$3.72 | $3.95 | $3.72 | $3.95 | $3.7 | 6,868 | 07-19-2024 |
$3.8101 | $4 | $3.8101 | $4.42 | $3.77 | 18,580 | 07-18-2024 |
$3.97 | $4.1 | $3.97 | $4.3499 | $3.9337 | 20,139 | 07-17-2024 |
$3.97 | $3.75 | $3.97 | $4.25 | $3.52 | 53,270 | 07-16-2024 |
$3.73 | $3.995 | $3.73 | $4.099 | $3.7075 | 180,861 | 07-15-2024 |
$0.412699 | $0.4138 | $0.412699 | $0.4495 | $0.3936 | 147,560 | 07-12-2024 |
$0.427 | $0.44 | $0.427 | $0.45 | $0.42 | 58,528 | 07-11-2024 |
$0.4416 | $0.447 | $0.4416 | $0.46 | $0.41 | 59,348 | 07-10-2024 |
$0.44 | $0.4598 | $0.44 | $0.4598 | $0.4301 | 154,115 | 07-09-2024 |
$0.4598 | $0.42 | $0.4598 | $0.469 | $0.413 | 149,111 | 07-08-2024 |
$0.3909 | $0.403 | $0.3909 | $0.41 | $0.38 | 62,042 | 07-05-2024 |
$0.39 | $0.3959 | $0.39 | $0.4199 | $0.3707 | 36,477 | 07-04-2024 |
$0.39 | $0.3959 | $0.39 | $0.419899 | $0.3707 | 36,477 | 07-03-2024 |
$0.396 | $0.4086 | $0.396 | $0.45 | $0.395 | 52,242 | 07-02-2024 |
$0.4087 | $0.391 | $0.4087 | $0.42 | $0.391 | 29,313 | 07-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...